Pseudomyxoma peritonei natural history, complications and prognosis: Difference between revisions
Jump to navigation
Jump to search
Nima Nasiri (talk | contribs) |
Nima Nasiri (talk | contribs) |
||
| Line 12: | Line 12: | ||
==Prognosis== | ==Prognosis== | ||
*Prognosis of pseudomyxoma peritonei is generally good because of change in treatment modalities, traditional [[debulking]] surgery replaced by cytoreductive surgery combined with [[hyperthermic intraperitoneal chemoperfusion]] (HIPEC).<ref name="pmid11373099">{{cite journal |vauthors=Sugarbaker PH |title=Cytoreductive surgery and peri-operative intraperitoneal chemotherapy as a curative approach to pseudomyxoma peritonei syndrome |journal=Eur J Surg Oncol |volume=27 |issue=3 |pages=239–43 |date=April 2001 |pmid=11373099 |doi=10.1053/ejso.2000.1038 |url=}}</ref> | *Prognosis of pseudomyxoma peritonei is generally good because of change in treatment modalities, traditional [[debulking]] surgery replaced by cytoreductive surgery combined with [[hyperthermic intraperitoneal chemoperfusion]] (HIPEC).<ref name="pmid11373099">{{cite journal |vauthors=Sugarbaker PH |title=Cytoreductive surgery and peri-operative intraperitoneal chemotherapy as a curative approach to pseudomyxoma peritonei syndrome |journal=Eur J Surg Oncol |volume=27 |issue=3 |pages=239–43 |date=April 2001 |pmid=11373099 |doi=10.1053/ejso.2000.1038 |url=}}</ref> | ||
*According to [[WHO]] classification, pseudomyxoma peritonei (PMP) divides into | *According to [[WHO]] classification, pseudomyxoma peritonei (PMP) divides into disseminated peritoneal adenomucinosis (DPAM) and peritoneal mucinous carcinomatosis (PMCA), with DPAM type having better prognosis with higher [[Survival rates|survival rate]] based on their histological [[morphology]], in contrast, tumors arising from [[colorectal]] [[neoplasm]] are usually high grades with bad prognosis.<ref name="CarrFinch2012">{{cite journal|last1=Carr|first1=Norman J|last2=Finch|first2=Jenny|last3=Ilesley|first3=Ian Charles|last4=Chandrakumaran|first4=Kandiah|last5=Mohamed|first5=Faheez|last6=Mirnezami|first6=Alex|last7=Cecil|first7=Tom|last8=Moran|first8=Brendan|title=Pathology and prognosis in pseudomyxoma peritonei: a review of 274 cases|journal=Journal of Clinical Pathology|volume=65|issue=10|year=2012|pages=919–923|issn=0021-9746|doi=10.1136/jclinpath-2012-200843}}</ref><ref name="pmid15048674">{{cite journal |vauthors=Mohamed F, Gething S, Haiba M, Brun EA, Sugarbaker PH |title=Clinically aggressive pseudomyxoma peritonei: a variant of a histologically indolent process |journal=J Surg Oncol |volume=86 |issue=1 |pages=10–5 |date=April 2004 |pmid=15048674 |doi=10.1002/jso.20038 |url=}}</ref><ref name="pmid7503361">{{cite journal |vauthors=Ronnett BM, Zahn CM, Kurman RJ, Kass ME, Sugarbaker PH, Shmookler BM |title=Disseminated peritoneal adenomucinosis and peritoneal mucinous carcinomatosis. A clinicopathologic analysis of 109 cases with emphasis on distinguishing pathologic features, site of origin, prognosis, and relationship to "pseudomyxoma peritonei" |journal=Am. J. Surg. Pathol. |volume=19 |issue=12 |pages=1390–408 |date=December 1995 |pmid=7503361 |doi= |url=}}</ref> | ||
==References== | ==References== | ||
Revision as of 17:22, 23 January 2019
|
Pseudomyxoma peritonei Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Pseudomyxoma peritonei natural history, complications and prognosis On the Web |
|
American Roentgen Ray Society Images of Pseudomyxoma peritonei natural history, complications and prognosis |
|
FDA on Pseudomyxoma peritonei natural history, complications and prognosis |
|
CDC on Pseudomyxoma peritonei natural history, complications and prognosis |
|
Pseudomyxoma peritonei natural history, complications and prognosis in the news |
|
Blogs on Pseudomyxoma peritonei natural history, complications and prognosis |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Nima Nasiri, M.D.[2]Parminder Dhingra, M.D. [3]
Overview
Pseudomyxoma peritonei is a rare disease characterized by the accumulation of mucinous ascites and mucinous tumor disseminated in the peritoneal cavity, mainly abdomen and pelvis; the disease mainly originates from primary appendiceal tumors and less commonly from the ovary and colon. In 2010, WHO published a classification which divides pseudomyxoma peritonei (PMP) into low and high grades. Cytoreductive surgery with hyperthermic intraperitoneal chemoperfusion (CRS/HIPEC) is the mainstay of treatment appendiceal pseudomyxoma peritonei (PMP).
Natural History
- Pseudomyxoma peritonei (PMP) is an uncommon disease characterized by mucinous ascites in intraperitoneal cavities, it is originating from a low-grade mucinous neoplasm of the appendix, if left untreated, patients with pseudomyxoma peritonei may progress to develop abdominal or pelvic pain, bloating, abdominal distension, weight change, and infertility due to compression impact of tumor on visceral organs.
- The tumor produces abundant mucins which accumulate because of gravity effect in the mesentery, the greater and lesser omentum, and under the diaphragm, around the liver and other visceral organs surfaces.
- The optimal treatment is cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemoperfusion (HIPEC).[1]
Prognosis
- Prognosis of pseudomyxoma peritonei is generally good because of change in treatment modalities, traditional debulking surgery replaced by cytoreductive surgery combined with hyperthermic intraperitoneal chemoperfusion (HIPEC).[2]
- According to WHO classification, pseudomyxoma peritonei (PMP) divides into disseminated peritoneal adenomucinosis (DPAM) and peritoneal mucinous carcinomatosis (PMCA), with DPAM type having better prognosis with higher survival rate based on their histological morphology, in contrast, tumors arising from colorectal neoplasm are usually high grades with bad prognosis.[3][4][5]
References
- ↑ Mittal R, Chandramohan A, Moran B (August 2017). "Pseudomyxoma peritonei: natural history and treatment". Int J Hyperthermia. 33 (5): 511–519. doi:10.1080/02656736.2017.1310938. PMID 28540829.
- ↑ Sugarbaker PH (April 2001). "Cytoreductive surgery and peri-operative intraperitoneal chemotherapy as a curative approach to pseudomyxoma peritonei syndrome". Eur J Surg Oncol. 27 (3): 239–43. doi:10.1053/ejso.2000.1038. PMID 11373099.
- ↑ Carr, Norman J; Finch, Jenny; Ilesley, Ian Charles; Chandrakumaran, Kandiah; Mohamed, Faheez; Mirnezami, Alex; Cecil, Tom; Moran, Brendan (2012). "Pathology and prognosis in pseudomyxoma peritonei: a review of 274 cases". Journal of Clinical Pathology. 65 (10): 919–923. doi:10.1136/jclinpath-2012-200843. ISSN 0021-9746.
- ↑ Mohamed F, Gething S, Haiba M, Brun EA, Sugarbaker PH (April 2004). "Clinically aggressive pseudomyxoma peritonei: a variant of a histologically indolent process". J Surg Oncol. 86 (1): 10–5. doi:10.1002/jso.20038. PMID 15048674.
- ↑ Ronnett BM, Zahn CM, Kurman RJ, Kass ME, Sugarbaker PH, Shmookler BM (December 1995). "Disseminated peritoneal adenomucinosis and peritoneal mucinous carcinomatosis. A clinicopathologic analysis of 109 cases with emphasis on distinguishing pathologic features, site of origin, prognosis, and relationship to "pseudomyxoma peritonei"". Am. J. Surg. Pathol. 19 (12): 1390–408. PMID 7503361.